SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

NBIS is trending following a multi-billion dollar agreement with Microsoft to provide AI infrastructure, fueling excitement around the company's growth potential in the AI cloud sector. The community is buzzing about the size and impact of the deal, with some suggesting it could lead to significant revenue growth and new all-time highs. Some analysts see the stock as undervalued given the broader context of increased AI infrastructure spending.

Eightco Holdings, Inc. is a publicly traded holding company, which operates in the consumer products and e-commerce markets, focusing on developing and deploying innovative technology, and capital solutions to empower small to medium-sized businesses. It operates through the North America and Europe geographical segments. The company was founded in 1966 and is headquartered in Easton, PA.

Eightco Holdings Inc

Eightco Holdings Inc ($OCTO) experienced extreme volatility, surging thousands of percentage points following news of a significant crypto treasury investment, leading to a frenzy among day traders and short sellers. The community is actively debating whether the massive gains are sustainable, with many pointing to potential dilution and insider selling, while others anticipate a continued squeeze. Speculation is high as traders look for the next stock to replicate $OCTO's meteoric rise, leading to increased attention on other low-float and crypto-related stocks.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending due to a live demonstration of its solid-state batteries powering a Ducati motorcycle, showcasing faster charging and higher energy density which has sparked optimism about the technology's potential and real-world application. The community is discussing the implications of this milestone, including potential partnerships with major automakers and the possibility of a short squeeze. However, some are cautious, pointing to the long timeline for commercial production and past disappointments.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital ($GLXY) is trending amid a boost from positive data center news related to $NBIS. Community members believe $GLXY is undervalued, given its significant data center infrastructure, with some speculating a new all-time high is coming. Others are closely watching for Q3 results and any updates regarding ERCOT approval.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is trending due to a proposed $300M private offering of convertible senior notes, announced after a positive earnings call, leading to concerns about dilution and prompting community discussion around the timing and necessity of the offering. While some investors see it as a strategic move for long-term growth and warrant management, others view it as a deceptive practice that takes advantage of retail investors after a strong earnings report. The community is actively debating the implications of the offering, including conversion prices, capped call strikes, and potential impact on share value and future growth prospects.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending amid community excitement, with some eyeing the .24 resistance level and speculating on potential ETF approvals. A recent acquisition of 285M DOGE by CleanCore to initiate its Dogecoin treasury strategy has also fueled bullish sentiment. Despite its meme coin origins, discussions around institutional adoption and potential for significant price movement are driving the conversation.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around upcoming burns, staking app launch, and new contests, fueling excitement. Chatter revolves around the strong community, often referred to as "chads", and the project's commitment to a long-term vision. The focus remains on community growth, with members highlighting the coin's organic rise and commitment to future utilities.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending due to news of Nebius entering a multi-billion dollar commercial agreement for AI infrastructure, sparking community excitement about the potential impact on both companies. Traders are also monitoring Microsoft's position in the AI landscape, especially compared to Nvidia, as Polymarket data indicates a strong belief in Nvidia's dominance by the end of the month. Community members are actively discussing the implications of this AI infrastructure deal.

Sentage Holdings, Inc. engages in the financial services, which offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China. The company was founded on September 16, 2019 and is headquartered in Shanghai, China.

Sentage Holdings Inc - Ordinary Shares - Class A

Sentage Holdings Inc

Sentage Holdings Inc is trending due to speculative interest, drawing comparisons to recent high-flying low floaters like $OCTO and $MGIH. Community chatter suggests anticipation for a potential short squeeze and after-hours momentum. Some traders are also noting the stock's low float and potential for significant price movement, while others caution about its fundamentals.

Casey's General Stores, Inc. engages in the provision of management and operation of convenience stores and gasoline stations. It provides self-service gasoline, a wide selection of grocery items, and an array of freshly prepared food items. The firm offers food, beverages, tobacco products, health and beauty aids, automotive products, and other non-food items. The company was founded by Donald F. Lamberti in 1968 and is headquartered in Ankeny, IA.

Casey`s General Stores, Inc.

Casey's General Stores, Inc.

CASY is trending as investors discuss the potential impact of upcoming earnings on the stock's trajectory, with community members debating whether it will be a bull trap or a sustained rally. The stock's valuation and recent performance are key points of contention, as some question whether it is overvalued, while others highlight its growth potential and dividend increases. Community members are also sharing information regarding recent news, analyst ratings, and historical performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?

Teva expects 2025 generics growth to be flat to low single digit, with U.S. trends and the Japan divestment influencing results.

Chinese pharmaceutical companies that once supplied ingredients for more than a billion makeshift doses of weight-loss drugs in the U.S. are apparently shifting their focus to generics as regulators crack down on compounded copies of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.Over the past two years, at least eight Chinese firms,&nbsp; including Jiangsu Sinopep-Allsino Biopharmaceutical and Hybio Pharmaceutical, shipped raw semaglutide and tirzepatide to the U.S., according to Reuters’&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/chinese-companies-turn-generics-shipments-behind-us-weight-loss-craze-fade-2025-09-02/">report</a>, citing FDA shipping data and public records.&nbsp;Sinopep and Hybio are now reportedly working to develop generic semaglutide, while Nanjing Hanxin Pharmaceutical and Fujian Genohope Biotech may follow.&nbsp;With U.S. law now restricting compounders to personalized doses or formulations not otherwise available, Chinese suppliers are eyeing markets where Novo’s key semaglutide patent is set to expire in 2026, including Canada and Brazil.&nbsp;However, producing semaglutide in&nbsp;its final injectable form is complex, and branded drugmakers could delay generic launches, according to a lawyer for a generic drugmaker.The regulatory shift has already choked supply. In the second quarter of 2025, U.S.-bound&nbsp;shipments of semaglutide and tirzepatide declined by approximately 90% and 34%,&nbsp;respectively, compared to the same quarter a year earlier. That marked a sharp reversal from 2024, when Chinese companies shipped enough semaglutide to make more than one billion starter doses.&nbsp;Novo told the U.S. Commerce Department that in just six months, Chinese exporters sent enough to make 1.5 billion Wegovy doses.The boom began after the FDA declared shortages in 2022, opening the door for compounding pharmacies, often supported by telehealth firms that grew during the pandemic, to sell cheap copies.&nbsp;Never before had a new drug become so wildly popular that the manufacturer simply couldn’t keep up, said Robert Califf, who has led the FDA twice, calling the compounding surge a “once-in-a-decade” issue.The economics were compelling. A 2024 JAMA report estimated&nbsp;that the production cost of&nbsp;semaglutide powder was only $0.07 per month, while Chinese suppliers could sell it at up to seven times that amount.&nbsp;U.S. compounding pharmacies were then able to offer injections at about $230 a month, which is less than half the price of branded versions.The fallout has been costly for Novo Nordisk, which missed quarterly sales targets and saw its shares cut in half in 2025, contributing to the ouster of its CEO in May.As shipments of semaglutide and tirzepatide dry up, some Chinese companies are shifting toward liraglutide, the active ingredient in older Novo drugs Saxenda and Victoza.&nbsp;Generic versions of liraglutide have been available in the U.S. since 2024 and are now promoted by telehealth sites that once pushed semaglutide. A wholesale supplier told Reuters he has seen demand for liraglutide climb.On Stocktwits, retail sentiment was ‘extremely bearish’ for Novo Nordisk and ‘bearish’ for Eli Lilly, with both seeing ‘extremely low’ message volume.While&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk’s U.S.-listed stock</a> has declined 33.2% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/LLY">Eli Lilly’s stock</a> dropped 4.2% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Injections for weight loss with Semaglutide. An obese woman gives a hormone glucagon-like peptide-1 (GLP-1) injection into the abdomen with a pen syringe.

Chinese Drugmakers Flooded US With Wegovy Copy Ingredients — Now They Are Pivoting To Generics: Report

As U.S. restrictions tighten, suppliers are targeting markets such as Canada and Brazil, where patents are set to expire in 2026.

Equity

GSK Adds Around $5B in a Month: Here's How to Play the Stock

GSK stock adds nearly $5B in value in a month as Specialty Medicines growth, pipeline wins and a strong outlook outweigh vaccine headwinds.

Danish drugmaker Novo Nordisk (NVO) has entered into a multi-year research collaboration with Replicate BioScience to develop new therapeutic candidates, the privately held clinical stage company stated on Thursday.The collaboration will bring together Novo’s therapeutic knowledge and drug development expertise with Replicate’s novel srRNA platform to develop new therapeutic candidates to treat obesity, type 2 diabetes, and other cardiometabolic diseases, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://replicatebioscience.com/replicate-bioscience-announces-partnership-with-novo-nordisk-to-unlock-self-replicating-rna-therapies-for-obesity-and-diabetes/">said</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVO">NVO stock</a> trended within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘low’ levels. According to Stocktwits data, retail chatter about the stock increased by about 157% over the past 30 days. Shares of the company traded 1% lower at the time of writing.<figure class="image"><img style="aspect-ratio:577/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_28_at_10_55_20_AM_png_5dd1ac88ba.webp" alt="NVO's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Aug. 28, 2025 | Source: Stocktwits" width="577" height="60"><figcaption>NVO's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Aug. 28, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that they have purchased more shares of the company.<stembedurl>https://stocktwits.com/bginvest/message/626846711</stembedurl>Under the new deal, Novo Nordisk will receive a defined, exclusive, and worldwide license to use Replicate’s self-replicating RNA platform for the development and commercialization of treatments. Meanwhile, Replicate will receive research funding and is eligible to receive up to $550 million from Novo, including an up-front cash payment and potential milestone payments. Replicate is also eligible to receive tiered royalties on future product sales as part of the deal.Last month, Novo, which is battling competition from its U.S. rival Eli Lilly, lowered its full-year 2025 outlook, citing lower growth expectations for its blockbuster weight loss drug Wegovy and diabetes drug Ozempic for the second half of the year.The firm now expects sales growth of 8% to 14% during the year at a constant exchange rate, down from its previous estimate of 13% to 21%. Operating profit growth is now expected to be 10% to 16%, down from its prior outlook of 16% to 24%.Last week, it was reported that the drugmaker has implemented a hiring freeze, which will apply across all markets and departments, with an exemption for business-critical roles. Former CEO of Novo Nordisk, Lars Fruergaard Jørgensen, had earlier stated that the company is taking measures to sharpen its commercial execution and ensure efficiencies in cost base while continuing to invest in future growth.NVO stock is down 35% this year and approximately 59% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/teva-pharma-announces-fda-approval-for-generic-weight-loss-medication/chs6ffWRdmt">This Pharma Stock Is Down 19% In 2025 But Just Received An ‘Explosive News’ – Find Out More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

This Pharma Major’s Stock Has Lost 59% Of Its Value In A Year – Why Is It Drawing Investor Interest Today?

Novo Nordisk has entered into a collaboration with Replicate BioScience under which it will receive a defined, exclusive, worldwide license to use the latter’s self-replicating RNA platform to develop and commercialize treatments.

Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet?

NVO and VKTX face setbacks and rising competition as they battle for ground in the GLP-1 obesity market.

Does Lilly's New Obesity Pill Data Put It Back in the Weight Game?

LLY's obesity pill orforglipron hits weight-loss and A1C goals in a phase III trial, lifting shares nearly 6% and reviving investor confidence.

LLY vs. PFE: Which Pharma Giant Is the Better Pick for Investors?

Pfizer's cost cuts, new products and cheaper valuation give it an edge over Eli Lilly despite LLY's strong GLP-1 momentum.

Can Novo Nordisk Offset GLP-1 Pressures With Rare Disease Wins?

NVO faces slowing GLP-1 momentum but leans on rare disease wins and new Wegovy approval to bolster growth.

AMGN Up Almost 14% YTD: Should You Buy, Sell or Hold the Stock?

Amgen's stock is up 13.5% in 2025, fueled by strong drug sales and new biosimilars, but looming competition and pricing headwinds pose challenges.

Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

NVO
Novo Nordisk A/S

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NVO News

NVO Novo Nordisk A/S